Amgen to buy experimental cancer drug maker Biovex in $1bn deal
Amgen, the world’s largest biotechnology company, said it agreed to buy Biovex, a closely-held maker of experimental cancer drugs for $425m plus as much as $575m in milestone payments.
Read more on Daily Telegraph
PolyMedix Promotes Bozena Korczak to Senior Vice President, Drug Development and Chief Development Officer
PolyMedix, Inc. , an emerging biotechnology company focused on developing new therapeutic drugs for the treatment of serious infectious diseases and acute cardiovascular disorders, announces the promotion of Bozena Korczak, Ph.D. to Senior Vice President, Drug Development and Chief Development Officer.
Read more on Business Wire via Yahoo! Finance
Bay Biz Buzz: Xoma to develop diabetes drug with French firm
Berkeley-based Xoma Ltd., an unprofitable 30-year- old biotechnology company, will get an initial payment of $35 million and may earn as much as $800 million more from Les Laboratoires Servier to share development of a medicine for diabetes and other disorders.
Read more on Inside Bay Area
www.StockMarketFunding.com Human Genome Sciences Benlysta Drug Approved for Lupus HGSI. FDA Approves Benlysta Human Genome Drug (HGSI) for Lupus Patients 50 Year Healthcare Development. Human Genome Sciences Benlysta Drug Approval HGSI FDA Panel. Tomorrow is the big day! We finally see how Human Genome Sciences Blockbuster Hopes on Lupus Drug Benlysta Pans Out based on Human Genome Sciences Benlysta® “FDA Panel Endorses a Drug to Treat Lupus” FDA Panel votes in favor of Benlysta stock expected to trade higher on Wednesday 17, 2010. FDA panel backs first new lupus drug in 50 years – Health News. Federal health experts on Tuesday voted in favor of the first new drug to treat Lupus in over 50 years. FDA Panel Recommends Approval Of Human Genome, Glaxo Lupus Drug. FDA Panel Endorses a Drug to Treat Lupus
Labcyte® Acoustic Platform Essential to Identification of Novel Cancer Drug Candidates
SUNNYVALE, Calif.–(BUSINESS WIRE)–Labcyte technology helps pharmaceutical companies identify new drug candidates
Read more on Business Wire
Novartis’ Sandoz Unit Working On Copy Of Roche Drug – Source
Novartis’ Sandoz Unit Working On Copy Of Roche Drug – Source
Read more on FOX Business
Phase III Data Published In Lancet Show Novartis Drug Zometa® Improves Overall Survival In Newly Diagnosed Multiple …
A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free survival (PFS) in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known …
Read more on Medical News Today
Biotech Stocks: Amarin, AMAG rally, but drug indexes fall
Amarin Corp. and AMAG Pharmaceuticals shares are rallying in recent trading as the drug sector’s two key indexes fall.
Read more on Market Watch
UBC Innovation Is Advanced By The Centre For Drug Research And Development And Licensed By Global Healthcare Company
The University of British Columbia (UBC) and the Centre for Drug Research and Development (CDRD) recently announced that Covidien, a leading global provider of healthcare products, has licensed an innovative drug-delivery platform technology invented by UBC researcher, Pieter Cullis
Read more on DrugDiscoveryOnline
Biotech Stocks: Merck, drug indexes drift south
Merck & Co. shares are trading lower early Tuesday following news that it has appointed its president, Kenneth Frazier, to succeed retiring CEO Richard Clark.
Read more on Market Watch
Powered by Yahoo! Answers
